Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott Expects RA Agent D2E7 To Capture 25% Of Market, Touts Production

Executive Summary

Abbott predicts it has existing production capacity for its rheumatoid arthritis treatment D2E7 (adalimumab) to serve the market up to five years, even at ambitious growth projections.

You may also be interested in...



Abbott Humira Marketing Will Challenge RA Competitors On Dosing, Efficacy

Abbott will highlight Humira dosing convenience, efficacy and price to encourage switching of rheumatoid arthritis patients from Amgen/Wyeth's Enbrel or Johnson & Johnson's Remicade

Abbott Humira Marketing Will Challenge RA Competitors On Dosing, Efficacy

Abbott will highlight Humira dosing convenience, efficacy and price to encourage switching of rheumatoid arthritis patients from Amgen/Wyeth's Enbrel or Johnson & Johnson's Remicade

Abbott D2E7 Monotherapy Use Should Afford Faster FDA Review, Abbott Says

Abbott is focusing on the need for a regular supply of an anti-TNF agent that can be dosed without methotrexate as a justification for requiring a faster review of D2E7 at FDA

Related Content

UsernamePublicRestriction

Register

PS038049

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel